Metabolic & GLP-1 Research
Incretin Agonists, Fat Metabolism & Exercise Mimetics
The most active area of peptide research in 2025–2026. From FDA-approved GLP-1 agonists to next-generation exercise mimetics and mitochondrial uncouplers — this category covers the full spectrum of metabolic intervention research.
At a Glance
Metabolic research encompasses multiple mechanistic approaches to energy balance, fat metabolism, and insulin sensitivity. GLP-1 receptor agonists dominate the clinical pipeline. Alongside them, researchers are exploring fundamentally different mechanisms — mitochondrial uncoupling (BAM15), exercise transcription factor activation (SLU-PP-332), NNMT inhibition (5-Amino-1MQ), and amylin-GLP-1 combinations (cagrilintide) — each targeting a distinct aspect of metabolic regulation.
The compound that redefined obesity pharmacology. Once-weekly GLP-1 agonist with 15–17% body weight reduction in STEP trials and FDA-approved cardiovascular outcomes data.
FDA Approved · Read overview →Dual receptor targeting produces 22.5% body weight reduction in SURMOUNT trials — exceeding semaglutide monotherapy. FDA approved as Mounjaro and Zepbound.
FDA Approved · Read overview →Phase 2 data showing 24.2% body weight reduction — the highest ever recorded pharmacologically. Adds glucagon-driven thermogenesis to dual agonism.
Phase 2 Clinical · Read overview →The amylin half of CagriSema. Activates area postrema satiety pathways distinct from GLP-1 — producing synergistic 22.7% weight reduction in Phase 2 combination trials.
Phase 3 Active · Read overview →C-terminal fragment of human GH retaining fat-metabolizing properties without IGF-1 elevation or insulin effects. Phase 2 human fat loss data; Phase 2 cartilage research.
Phase 2 Clinical · Read overview →CNS-acting triple reuptake inhibitor with 10–13% weight loss in Phase 2b. Addresses the central reward and motivation dimension of appetite — different mechanism from all GLP-1 agents.
Phase 2 Clinical · Read overview →Selective mitochondrial proton uncoupler. Increases fat oxidation and metabolic rate without the dangerous hyperthermia of historical uncouplers like DNP.
Early Preclinical · Read overview →Activates estrogen-related receptor alpha — the transcription factor that governs mitochondrial biogenesis and fat oxidation in response to exercise. Preclinical endurance improvement data.
Early Preclinical · Read overview →Inhibits nicotinamide N-methyltransferase — overexpressed in obese fat cells, depleting NAD+ precursors and locking adipocytes in an energy-storing state. Novel epigenetic mechanism.
Early Preclinical · Read overview →Microprotein encoded in mitochondrial DNA. Activates AMPK, mimics exercise adaptation, and declines with age. Circulating MOTS-c restoration is a longevity research target.
Preclinical + Emerging Clinical · Read overview →All compounds listed are for laboratory research use only. Not for human or veterinary use. Information based on publicly available scientific literature as of 2026. · Helixera Labs LLC © 2026